SCHEMBL417797

SCHEMBL417797

O=S(=O)(On1nnc2ccc(Cl)cc21)c1ccc(Cl)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.48
MEN1 O00255 3/20 0.48
CYP2C19 P33261 1/20 0.46
ALDH1A1 P00352 6/20 0.43
SMN1; SMN2 Q16637 3/20 0.43
HPGD P15428 2/20 0.43
KMO O15229 1/20 0.41
POLB P06746 1/20 0.41
TSHR P16473 2/20 0.39
CASP3 P42574 1/20 0.39
SENP8 Q96LD8 1/20 0.39
SENP7 Q9BQF6 1/20 0.39
SENP6 Q9GZR1 1/20 0.39
CUL4A Q13619 1/20 0.38
KDM4E B2RXH2 1/20 0.37
HTT P42858 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
CRHBP P24387 1/20 0.36
RECQL P46063 1/20 0.36
CRHR2 Q13324 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7383122 0.92 KMT2A (0.45) KMT2AMEN1CYP2C19ALDH1A1SMN1; SMN2
SCHEMBL3724640 0.92 SMN1; SMN2 (0.47) KMT2AMEN1CYP2C19ALDH1A1SMN1; SMN2
SCHEMBL11450688 0.86 CYP2C19 (0.40) KMT2AMEN1CYP2C19ALDH1A1SMN1; SMN2
SCHEMBL9817222 0.86 CYP2C19 (0.59) KMT2ACYP2C19ALDH1A1SMN1; SMN2HPGD
SCHEMBL11450733 0.82 KMT2A (0.50) KMT2AMEN1CYP2C19ALDH1A1SMN1; SMN2
SCHEMBL7114768 0.81 SMN1; SMN2 (0.47) KMT2AMEN1CYP2C19ALDH1A1SMN1; SMN2
SCHEMBL11467472 0.79 KMT2A (0.47) KMT2AMEN1CYP2C19ALDH1A1SMN1; SMN2
SCHEMBL9755876 0.79 ALDH1A1 (0.34) KMT2AMEN1CYP2C19ALDH1A1HPGD
SCHEMBL11450055 0.77 TDP1 (0.37) KMT2AMEN1ALDH1A1SMN1; SMN2TSHR
SCHEMBL11450048 0.75 ALDH1A1 (0.47) KMT2AMEN1CYP2C19ALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1136 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-57035574-A None JP disclosed
US-20260137765-A1 METHODS OF PRODUCING SHIGA TOXIN B-SUBUNIT (STXB) MONOMERS AND OLIGOMERS, AND USES THEREOF INSTITUT CURIE (FR) 2026-05-21 US disclosed
US-20260108497-A1 OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION OTSUKA PHARMACEUTICALC., LTD. (JP) 2026-04-23 US disclosed
EP-4707284-A1 HETEROCYCLIC COMPOUND AND USE THEREOF Otsuka Pharmaceutical Co., Ltd. (JP) 2026-03-11 EP disclosed
US-12527854-B2 Methods of producing Shiga toxin B-subunit (STxB) monomers and oligomers, and uses thereof INSTITUT CURIE (FR) 2026-01-20 US disclosed
WO-2025089370-A1 COMPOUNDS AS CSF1R INHIBITORS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2025-05-01 WO disclosed
US-20250051310-A1 BENZAZEPINE DERIVATIVES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2025-02-13 US disclosed
WO-2024228399-A1 HETEROCYCLIC COMPOUND AND USE THEREOF 大塚製薬株式会社 2024-11-07 WO disclosed
US-20240286999-A1 AZABICYCLO[3.1.0]HEXANE COMPOUND OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2024-08-29 US disclosed
US-20240148699-A1 OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2024-05-09 US disclosed
US-4191762-A CEPHALOSPORIN BACTERICIDES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1980-03-04 US disclosed
US-4190448-A ACRYLIC ACID POLYMER CROSSLINKED WITH POLYHYDRIC ALCOHOL IN PRESENCE OF CONDENSATION-TYPE CROSSLINKING AGENT FUJI PHOTO FILM CO., LTD. (JP) 1980-02-26 US disclosed
EP-0007594-A1 Process for the preparation of high molecular-weight polyurethanes, soluble in organic solvents, from the usual reagents and in combination with bis-aminopropyl-polytetrahydrofuranes BASF Aktiengesellschaft (DE) 1980-02-06 EP disclosed
EP-0007470-A2 Cephem compounds, processes for their preparation and pharmaceutical compositions containing them FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1980-02-06 EP disclosed
EP-0007633-A2 Cephem compounds, processes for their preparation and pharmaceutical compositions containing them FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1980-02-06 EP disclosed
US-4181800-A ANTIBIOTICS FROM SUBSTITUTED PERHYDRO-S-TRIAZINES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1980-01-01 US disclosed
US-4172198-A ANTIBIOTICS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1979-10-23 US disclosed
US-4152433-A ANTIBIOTICS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1979-05-01 US disclosed
EP-0001125-A2 Cephalosporin derivatives, processes for their preparation and pharmaceutical compositions containing them FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1979-03-21 EP disclosed
EP-0000644-A2 Lower cycloalkyl substituted-benzene derivatives, the preparation thereof and their pharmaceutical compositions FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1979-02-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12527854-B2 Methods of producing Shiga toxin B-subunit (STxB) monomers and oligomers, and uses thereof STXBP1, RNGTT, UPF1 KMT2A 1584/4885MEN1 1288/4885CYP2C19 4867/4885
US-20240148699-A1 OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION PDE3B, PDE4A, PDE3A KMT2A 2947/4885MEN1 1962/4885CYP2C19 31/4885
US-20260108497-A1 OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION PDE7B, PDE4B, PDE1B KMT2A 3262/4885MEN1 2691/4885CYP2C19 33/4885
US-20240286999-A1 AZABICYCLO[3.1.0]HEXANE COMPOUND MALT1, CXCR1, AZI2 KMT2A 1209/4885MEN1 256/4885CYP2C19 510/4885
US-20260137765-A1 METHODS OF PRODUCING SHIGA TOXIN B-SUBUNIT (STXB) MONOMERS AND OLIGOMERS, AND USES THEREOF STXBP1, HBB, UPF1 KMT2A 1769/4885MEN1 1342/4885CYP2C19 4877/4885
US-20250051310-A1 BENZAZEPINE DERIVATIVES AVPR2, AVPR1A, AVPR1B KMT2A 701/4885MEN1 356/4885CYP2C19 362/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.